Unenhanced MRI of the abdomen and pelvis for surveillance of patients with stage 1 testicular cancer post-radical orchiectomy

Author(s):  
Rishi Narine ◽  
Heba Osman ◽  
Sirote Wongwaisayawan ◽  
Scott Morgan ◽  
Luke T. Lavallee ◽  
...  
2017 ◽  
Vol 11 (1-2) ◽  
pp. 35 ◽  
Author(s):  
Rachel Glicksman ◽  
Robert J. Hamilton ◽  
Peter Chung

Treatment of testicular cancer is dependent on the stage of disease at presentation. Stage 1 testicular cancer is treated with radical orchiectomy, followed by active surveillance, radiotherapy, or chemotherapy. Occasionally, unusual and unexpected postoperative changes can be seen on computed tomography (CT), and may raise concern for metastatic disease.Here, we present two cases of testicular cancer patients who developed retroperitoneal hematomas post-radical orchiectomy, one as a classical clinical presentation, and the other as an atypicalradiological entity only. The first is a case of a 38-year-old male with a non-seminoma testicular cancer, who developed severe flank pain, hemodynamic instability, and progressive anemia from a retroperitoneal hematoma in the immediate (<24 hours) postoperative period, requiring urgent surgical evacuation. The second is a case of a 33-year-old male with a testicular seminoma who had a large, suspicious retroperitoneal mass on a staging CT scan concerning for metastatic disease, which was later diagnosed asa retroperitoneal hematoma. These cases reveal the clinical variability with which a retroperitoneal hematoma post-radical orchiectomy may present. In addition, the second case demonstrates the importance of recognizing radiological postoperative changes and ensuring that these findings are not mistaken for and treated as metastatic disease.


2015 ◽  
Vol 112 ◽  
pp. 135
Author(s):  
Yutaka Fujisue ◽  
Junko Kono ◽  
Yatsugu Kotake ◽  
Hiroshi Masuda ◽  
Yoshiki Yamashita ◽  
...  

2009 ◽  
Vol 181 (4S) ◽  
pp. 199-199
Author(s):  
Abdulaziz Baazeem ◽  
Jason M Boman ◽  
Philippe Violette ◽  
Armand Zini

2010 ◽  
Vol 20 (7) ◽  
pp. 1624-1630 ◽  
Author(s):  
Martin E. O’Malley ◽  
Peter Chung ◽  
Masoom Haider ◽  
Hyun-Jung Jang ◽  
Kartik Jhaveri ◽  
...  

2016 ◽  
Vol 9 (2) ◽  
pp. 84-92
Author(s):  
Elsie Ellimah Mensah ◽  
David Nicol ◽  
Erik Mayer

2011 ◽  
Vol 29 (6) ◽  
pp. 719-725 ◽  
Author(s):  
Torgrim Tandstad ◽  
Rune Smaaland ◽  
Arne Solberg ◽  
Roy M. Bremnes ◽  
Carl W. Langberg ◽  
...  

Purpose A binational, population-based treatment protocol was established to prospectively treat and follow patients with seminomatous testicular cancer. The aim was to standardize care for all patients with seminoma to further improve the good results expected for this disease. Patients and Methods From 2000 to 2006, a total of 1,384 Norwegian and Swedish patients were included in the study. Treatment in clinical stage 1 (CS1) was surveillance, adjuvant radiotherapy, or adjuvant carboplatin. In metastatic disease, recommended treatment was radiotherapy in CS2A and cisplatin-based chemotherapy in CS2B or higher. Results At a median follow-up of 5.2 years, 5-year cause-specific survival was 99.6%. In CS1, 14.3% (65 of 512) of patients relapsed following surveillance, 3.9% (seven of 188) after carboplatin, and 0.8% (four of 481) after radiotherapy. We could not identify any factors predicting relapse in CS1 patients who were subjected to surveillance only. In CS2A, 10.9% (three of 29) patients relapsed after radiotherapy compared with no relapses in CS2A/B patients (zero of 73) treated with chemotherapy (P = .011). Conclusion An international, population-based treatment protocol for testicular seminoma is feasible with excellent results. Surveillance remains a good option for CS1 patients. No factors predicted relapse in CS1 patients on surveillance. Despite resulting in a lower rate of relapse than with adjuvant carboplatin, adjuvant radiotherapy has been abandoned in the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) as a recommended treatment option because of concerns of induction of secondary cancers. The higher number of relapses in radiotherapy-treated CS2A patients when compared with chemotherapy-treated CS2A/B patients is of concern. Late toxicity of cisplatin-based chemotherapy versus radiotherapy must be considered in CS2A patients.


2011 ◽  
Vol 47 ◽  
pp. S511
Author(s):  
B. Houqhton ◽  
M. Stockier ◽  
M.D. Chatfield ◽  
G. Toner ◽  
I.D. Davis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document